Phase 2 proof-of-concept IPF trial
FDA Clears ArkBio to Begin U.S. Trial of Anti‑Fibrotic AK3280
Strategic Clinical Milestone Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for idiopathic pulmonary fibrosis (IPF). This clearance enables ArkBio to initiate a Phase 2 proof-of-concept clinical trial in the United States, marking a…
